Zhuotao Fu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zhuotao Fu has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Cong Meng
The Affiliated Traditional Chinese Medicine Hospital, Guangzhou Medical University Guangzhou China
2 shared publications - Zhitong Deng
Haikou Hospital of Traditional Chinese Medicine Haikou China
2 shared publications - Donghua Liu
First Affiliated Hospital of Guangzhou University of Chinese Medicine Guangzhou China
1 shared publication - Guoyi Li
Science and Technology Innovation Center, Guangzhou University of Chinese Medicine Guangzhou China
1 shared publication - Haodong Huang
The Affiliated TCM Hospital of Guangzhou Medical University, Guangzhou, China
1 shared publication - Jiawen Huang
Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, 510405, China
1 shared publication
Latest Publications
- Open Access
- 19 April 2026
- Published by Wiley in Food Science & Nutrition
- Vol. 14 (4) , e71798
Zhenyuan Solid Drink Ameliorates Inflammation and Oxidative Stress in Isoproterenol‐Induced Ischemic Myocardial Infarction via TLR4 / NF ‐ κB Pathway and PI3K / AKT1 / NRF2 Pathway in Rats
Zhenyuan Solid Drink (ZYSD) is a formulation consisting of 6 medicinal herbs that can be used as both food and medicinal materials in China. This comprehensive analysis aims to illuminate the potential therapeutic effects and underlying mechanisms of ZYSD in the context of ischemic myocardial infarction. Marker components in ZYSD were identified by high performance liquid chromatography (HPLC) through comparison with reference compounds. Isoproterenol (ISO)‐induced rats were employed as the in vivo model of ischemic myocardial infarction. Subsequently, a multi‐tiered approach integrating cardiac color Doppler ultrasound, cardiac enzyme marker analysis, inflammatory factor detection, gut microbiota profiling, network pharmacology, molecular docking, molecular dynamics (MD) simulation, and western blot analysis was employed to elucidate the effects and underlying mechanisms of ZYSD, with intervention in alleviating metoprolol tartrate as positive control. Ten compounds, derived from 6 medicinal plants, in ZYSD were identified as marker components for the quality control via HPLC. Animal studies confirmed the preventive and therapeutic efficacy of ZYSD against ischemic myocardial infarction, as evidenced by the improvement of cardiac function and the attenuation of inflammation and oxidative stress. Using network pharmacology and molecular docking, the active constituents including marker compounds of ZYSD exhibited strong binding affinity to their key targets, including AKT1 and NRF2. MD simulation further indicated the binding interaction between ZYSD components and AKT1. Western blot analysis results further verified that ZYSD regulates the TLR4/NF‐κB pathway and PI3K/AKT1/NRF2 pathway. Collectively, our findings demonstrate that ZYSD mitigates inflammation and oxidative stress, potentially through the TLR4/NF‐κB and PI3K/AKT1/NRF2 pathways, thereby providing a novel strategy for the prevention and treatment of ischemic myocardial infarction.
- 19 April 2026
- Published by Wiley in Food Science & Nutrition
- Vol. 14 (4) , e71798
Open AccessZhenyuan Solid Drink Ameliorates Inflammation and Oxidative Stress in Isoproterenol‐Induced Ischemic Myocardial Infarction via TLR4 / NF ‐ κB Pathway and PI3K / AKT1 / NRF2 Pathway in Rats
Zhenyuan Solid Drink (ZYSD) is a formulation consisting of 6 medicinal herbs that can be used as both food and medicinal materials in China. This comprehensive analysis aims to illuminate the potential therapeutic effects and underlying mechanisms of ZYSD in the context of ischemic myocardial infarction. Marker components in ZYSD were identified by high performance liquid chromatography (HPLC) through comparison with reference compounds. Isoproterenol (ISO)‐induced rats were employed as the in vivo model of ischemic myocardial infarction. Subsequently, a multi‐tiered approach integrating cardiac color Doppler ultrasound, cardiac enzyme marker analysis, inflammatory factor detection, gut microbiota profiling, network pharmacology, molecular docking, molecular dynamics (MD) simulation, and western blot analysis was employed to elucidate the effects and underlying mechanisms of ZYSD, with intervention in alleviating metoprolol tartrate as positive control. Ten compounds, derived from 6 medicinal plants, in ZYSD were identified as marker components for the quality control via HPLC. Animal studies confirmed the preventive and therapeutic efficacy of ZYSD against ischemic myocardial infarction, as evidenced by the improvement of cardiac function and the attenuation of inflammation and oxidative stress. Using network pharmacology and molecular docking, the active constituents including marker compounds of ZYSD exhibited strong binding affinity to their key targets, including AKT1 and NRF2. MD simulation further indicated the binding interaction between ZYSD components and AKT1. Western blot analysis results further verified that ZYSD regulates the TLR4/NF‐κB pathway and PI3K/AKT1/NRF2 pathway. Collectively, our findings demonstrate that ZYSD mitigates inflammation and oxidative stress, potentially through the TLR4/NF‐κB and PI3K/AKT1/NRF2 pathways, thereby providing a novel strategy for the prevention and treatment of ischemic myocardial infarction.
- Open Access
- 18 July 2022
- Published by Royal Society of Chemistry (RSC) in Food & Function
- Vol. 13 (17) , 8829-8849
The different effects of psyllium husk and orlistat on weight control, the amelioration of hypercholesterolemia and non-alcohol fatty liver disease in obese mice induced by a high-fat diet
Obesity is a widespread medical problem, for which many drugs have been developed, each with its own limitations. Orlistat, a lipase inhibitor, functions as a fat absorption blocker and is a widely used over-the-counter drug in China. Psyllium husk, in contrast, is a food source rich in dietary fibre and is beneficial for weight loss because it reduces appetite. Here, it was investigated how psyllium husk treatments affect mice with a high-fat diet (HFD)-induced obesity, using obesity-related indices, metabolism indices, and gut microbiota, compared to orlistat treatments. Orlistat had a greater effect on weight loss, whereas psyllium husk had a greater effect at reducing serum and liver cholesterol and triglyceride levels. Treatments had similar effects on controlling the body fat rate, the expression level of farnesoid X receptor, sterol 27-hydroxylase and oxysterol 7-hydroxylase (CYP7B1) in the liver, and the regulation of major bile acids such as cholic acid, chenodeoxycholic acid, deoxycholic acid, and lithocholic acid in faecal content. However, the expression of CYP7A1 in the liver and the structures of faecal bile acids were different between the two drugs. Furthermore, although they also had similar effects on the gut microbiota at the phylum level, there were differences at the genus level for Roseburia, Bacteroides, Faecalibacterium, Coprobacillus, and Akkernansia, which led to the difference in the serum lipopolysaccharide (LPS) level. Orlistat increased the food intake of the obese mice that were fed a HFD, which led to an increase in water intake, serum triglyceride levels, and lower glucose tolerance. Although orlistat is considered a suitable drug for weight loss, psyllium husk is a comparatively more cost-effective choice for ameliorating hypercholesterolemia and non-alcoholic fatty liver disease caused by a HFD.
- 18 July 2022
- Published by Royal Society of Chemistry (RSC) in Food & Function
- Vol. 13 (17) , 8829-8849
Open AccessThe different effects of psyllium husk and orlistat on weight control, the amelioration of hypercholesterolemia and non-alcohol fatty liver disease in obese mice induced by a high-fat diet
Obesity is a widespread medical problem, for which many drugs have been developed, each with its own limitations. Orlistat, a lipase inhibitor, functions as a fat absorption blocker and is a widely used over-the-counter drug in China. Psyllium husk, in contrast, is a food source rich in dietary fibre and is beneficial for weight loss because it reduces appetite. Here, it was investigated how psyllium husk treatments affect mice with a high-fat diet (HFD)-induced obesity, using obesity-related indices, metabolism indices, and gut microbiota, compared to orlistat treatments. Orlistat had a greater effect on weight loss, whereas psyllium husk had a greater effect at reducing serum and liver cholesterol and triglyceride levels. Treatments had similar effects on controlling the body fat rate, the expression level of farnesoid X receptor, sterol 27-hydroxylase and oxysterol 7-hydroxylase (CYP7B1) in the liver, and the regulation of major bile acids such as cholic acid, chenodeoxycholic acid, deoxycholic acid, and lithocholic acid in faecal content. However, the expression of CYP7A1 in the liver and the structures of faecal bile acids were different between the two drugs. Furthermore, although they also had similar effects on the gut microbiota at the phylum level, there were differences at the genus level for Roseburia, Bacteroides, Faecalibacterium, Coprobacillus, and Akkernansia, which led to the difference in the serum lipopolysaccharide (LPS) level. Orlistat increased the food intake of the obese mice that were fed a HFD, which led to an increase in water intake, serum triglyceride levels, and lower glucose tolerance. Although orlistat is considered a suitable drug for weight loss, psyllium husk is a comparatively more cost-effective choice for ameliorating hypercholesterolemia and non-alcoholic fatty liver disease caused by a HFD.